Ibrahim Shahoub, MD
Pulmonary Disease · Lexington, KYNPI 1629410691
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,776 of the $2,596 with a category attached, or 68.4%. Covidien LP accounts for 87.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $2,281 and has fallen 96.5% since, to $79 in 2025. That places this record below the midpoint for pulmonary disease clinicians in KY, where the typical reported total is $4,124.
Across 31 payments — averaging $83.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$2K
- GSK$76
- AbbVie$58
- Actelion Pharmaceuticals US, Inc.$29
- Melinta Therapeutics, LLC$21
- AstraZeneca$21
- plus $111 from 7 others
What the payments were for
- Travel & lodging$1,77668%
- Food & beverage$80931%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 12 | $2,281 |
| GSK | 5 | $76 |
| AbbVie | 4 | $58 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Melinta Therapeutics, LLC | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Abbott | 1 | $19 |
| Medtronic | 1 | $19 |
| Verona Pharma, Inc. | 1 | $17 |
| Amgen | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$1,841
How this compares
$2,596 in reported general payments places this provider in the 40th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $454 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Lexington
- Dennis DohertyLexington$103K
- Ashish MaskeyLexington$94K
- Girish NairLexington$86K
- John ThompsonLexington$77K
- Anthony GerberLexington$20K
- Eliseo Colon-CarrerasLexington$17K
- Christopher MeenachLexington$15K
- Theresa CaseLexington$14K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.